PriceSensitive

Nextleaf Solutions (CSE:OILS) awarded U.S. patent for synthesizing THC-O-Acetate

Cannabis
CSE:OILS
16 April 2021 10:30 (EDT)

Nextleaf has been awarded a patent for the modification of THC into a more potent prodrug version of THC-O-acetate.

Nextleaf believes the THC-derived prodrug produced under its patented process may hold potential as a therapeutic product for the treatment of chronic pain, PTSD, and alcohol use disorder.

“The U.S. continues to be the focal point of our global IP strategy,” said Nextleaf CEO Paul Pedersen.

“Between operating our cannabinoid innovation lab under strict federal regulations in Canada where cannabis is federally legal and owning one of the largest U.S. patent portfolios of any cannabis company, Nextleaf has the type of robust intellectual property portfolio and scalable commercial platform that large pharmaceuticals and big tobacco companies have already targeted with M&A in 2021.”   

“This U.S. patent covers our method of THC acetylation and follows our previous patent for synthesizing THC-O-acetate, with improvements to reaction efficiencies,” said Nextleaf Solutions R&D Lead, Dr. David Novitski.

“Our latest patented method reduces processing time and costs, which are critical when scaling up any drug delivery technology, and THC-O-acetate is no different.” 

“To the best of our knowledge, Nextleaf is the first company in the world, publicly traded or private, to be issued patents for the production of THC-O-Acetate, a specialty molecule not legally available anywhere in the world,” said Pedersen. 

Nextleaf Solutions is an innovative cannabis processor that owns one of the largest portfolios of U.S. patents for the extraction, distillation, and delivery of cannabinoids.

Nextleaf Solutions is unchanged, trading at C$0.26 per share at 10:30 am ET.

Related News